Migrastatin and isomigrastatin analogues have been synthesised in order to contribute to structure-activity studies on tumour cell migration inhibitors. These include macrocycles varying in ring size, functionality and alkene stereochemistry, as well as glucuronides (macrolides). The synthesis work included application of Saegusa-Ito reaction for regio-and stereoselective unsaturated macroketone formation, diastereoselective Brown allylation to generate 9-methylmigrastatin analogues and chelation induced anomerisation to vary glucuronide configuration. Compounds were tested in vitro against both breast and pancreatic cancer cell lines and inhibition of tumour cell migration was observed in both wound-healing (scratch) and Boyden chamber assays. One unsaturated macroketone showed low affinity for a range of secondary drug targets, indicating it is at low risk of displaying adverse side effects [a] 
Introduction
Tumour metastasis is a process where cancer cells detach from a primary tumour, migrate and then colonize a distant organ and the process leads to mortality for cancer patients. [1] Small molecules that interfere with tumour cell migration [2] have significant potential as anti-metastatic drugs [3] or as tools [4] for the study of tumour cell migration. Migrastatin 1, is a natural product that inhibits tumour cell migration (µM range) in vitro. Truncated [5] or simpler analogues of migrastatin, such as 2, 3, MGSTA-4 and MGSTA-5 (Figure 1) , prepared in Danishefsky's laboratory, [6] have been reported to show orders of magnitude higher activity than migrastatin itself in vitro and both 3 and MGSTA-5 [7] and other compounds [8] have demonstrated inhibitory activity in vivo. We have been engaged in the synthesis of migrastatin analogues [9] and recently through collaboration with Anderson and Nobis have shown that macroketone MGSTA-5 inhibited Ecadherin dynamics in vivo, in a manner consistent with increased cell adhesion and reduced invasive potential. [10] It has been reported that the target for MGSTA-5 is fascin, which is recognized as being involved in cell motility and migration processes and is upregulated in many human tumours as well as in several cancer cell lines including breast [11] , pancreatic. [12] and colon cancer cells. [13] Importantly, fascin is also involved in the chemotherapeutic resistance of breast. [14] and colon [15] cancer cells. However, whether fascin is the target for MGSTA-5 is still debated [16] and there is a belief that there may be other unidentified target(s) of migrastatin and its analogues. [16] Figure 1. a) Migrastatin (1) and truncated analogues 2-3 IC50 values (in parentheses) in Boyden chamber assay against 4T1 mouse mammary cancer cells. [6] b) Modification of migrastatin-core in this paper For these reasons the synthesis of analogues of migrastatin, including new analogues, continues to be of interest [6, 8, 17] [7, 16b, 18] [19] . Here we report the the preparation and migrastatin analogues shown in Figure 2 . The modifications have included variation in macrocycle ring size and functionality within the ring as well as varying alkene geometry and glucuronidation. Included are the syntheses of related isomigrastatin analogues. The reasons for synthesis of these various analogues include attempts to generate analogues to ultimately contribute to the structure-activity relationships and to try to identify more potent analogues. The activity of selected compounds in relevant bioassays was subsequently investigated and results of these are described.
Synthesis of isomigrastatin analogues
Isomigrastatin 18, a natural product isolated from Streptomyces platensis [21] and a precursor to migrastatin and it is a potent inhibitor of tumour cell migration. [17d] In view of this, we have used monoprotected diol 19, readily available in 4 steps from 4, [10] for the preparation of truncated isomigrastatins. Firstly the direct exchange of the OH in 19 for Br was attempted, but when 19 was treated with polymer bound Ph3P and CBr4 in CH2Cl2, the methoxy group at C-4 migrated to the C-1 position giving allylic bromide 20 (68%), with no trace of the desired compound being found. Attempts to form the tosylate or chloride from 19 led to complex reaction mixtures. On the other hand, when 19 was coupled with carboxylic acid 6b under Mitsunobu conditions, the desired ester 22 was isolated in a 57% yield together with a small amount of rearranged compound 21 (14 %) . With 22 in hand, RCM was next attempted. Unfortunately, reaction of 22 with the Grubbs-II in toluene only gave a complex mixture (TLC evidence) and the desired product was not detected (MS and 1 H-NMR spectroscopic evidence). The TBS group was removed from 22 and the secondary alcohol generated then protected as the MOM ether 23. In this case, 23 readily cyclized using Grubb's 2 nd to afford macrocycle 24 (Scheme 2) as previously described. [22] A mechanistic proposal for formation of 20 and 21 is suggested in Scheme 2 B. Scheme 2. A) Reagent and conditions: (a) CBr4, Ph3P polymer-bound, CH2Cl2, rt; 1h, 68%; (b) 6b, Ph3P, DIAD, PhCH3, rt; 57%; (c) TBAF, THF, rt, 3 days, 60%; (d) MOMCl, CH2Cl2, Hunig's base, 0 o C to rt, 18h, 60%; (e) Grubbs-II catalyst, PhCH3, reflux; 31% 1 IC50 values using 4T1 mouse mammary adenocarcinoma cells. 2 IC50 values using MDA-MB-231 human breast adenocarcinoma cells [17d] ; B) Proposed mechanism for formation of 20 and 21 under Mitsunobu and Appel conditions.
Synthesis of 9-methylmacrolactone analogues of migrastatin and isomigrastatin.
Brown allylation was used as the key step to generate an analogue bearing a methyl group instead of methoxy group at C-9. Thus Brown allylation [23] of 25 (Scheme 3) with cis-butene and β-methoxydiisopinocampheylborane installed two contiguous stereocenters with subsequent removal of the benzoate group enabling diol 26 to be isolated in moderate yield; the relative configuration was determined by obtaining an X-ray crystal structure determination for 26. Diol 26 was then protected as its di-O-TBS ether and subsequent treatment with 10% TsOH in MeOH removed the TBS group from the primary position to give the alcohol 27. This alcohol 27 was oxidized with the Dess-Martin periodinane and the aldehyde obtained was then treated with the Ando phosphonate [17b, 17k, 24] 35 to give 28. Reduction of the ester group in 28 using DIBAL-H gave a primary alcohol and its subsequent Mitsunobu reaction gave 29. However, RCM of 29, under several conditions and reaction time, only gave complex reaction mixtures (TLC) with no trace of the desired product. Alcohol 32 was prepared with a view to resolving this problem and for application in isomigrastatin analogue synthesis. Since the presence of the TBS group was problematic in the attempted RCM with compound 22, the secondary alcohol was protected as its MOM ether. Regioselective protection of the primary alcohol in 26 with a TBDPS group gave 30 and subsequent protection of its secondary alcohol as MOM ether afforded the orthogonally protected alkene 31 which gave 32 after TBDPS removal. The Mitsunobu reaction of 32 gave MGSTA-10. Ring-closing metathesis of MGSTA-10 afforded cis and trans alkene containing macrocycles MGSTA-11 and MGSTA-12 in a 1:0.85 ratio. The MOM protecting group was removed from both intermediates using TMSBr to give truncated isomigrastatin analogues MGSTA-13 and MGSTA-14. For the synthesis of migrastatin-core analogue MGSTA-15 bearing the methyl group at C-9, the primary alcohol 32 was oxidized using the Dess-Martin periodinane, and then treated with the Ando phosphonate [17b, 17k, 24] 35 giving the trisubstituted alkene 33, with the Z configuration.
The configuration of the newly formed double bond was supported by NOE spectroscopic experiments, where NOEs were observed for 33 as indicated in Scheme 3. The reduction of 33 with DIBALH and subsequent esterification using Mitsunobu conditions gave the RCM precursor to S6. As for 29, the RCM reaction of this precursor was unsuccessful and macrocyclic product could not be detected under several reaction conditions. Fortunately, addition of 1,4-benzoquinone [25] to the reaction mixture led to formation of desired 34 in modest yield, which after deprotection afforded the 9-methyl-macrolactone MGSTA-15.
Synthesis of migrastatin glucuronides
Glucuronides are an important class of phase 2 metabolites and glucuronidation in vivo of small molecules usually leads to compounds with higher water solubility, which are more easily excreted through the kidney. [26] Glucuronide metabolites are often biologically inactive but in some cases can display interesting bioactivity. [27] [28] The 6-O-glucuronide of morphine (M6G) displays full agonist properties at the µ1 opioid receptor and appears to be more potent than morphine itself with fewer side effects. [26, 29] In addition, the glucuronide of ezetimibe, a selective inhibitor of cholesterol absorption, is more active than ezetimibe itself. [26] [30] The biological activity of thiocolchicoside, a myorelaxant used for painful muscle contraction, has to be attributed to the presence of the 3-O-glucuronidated aglycone. [26] A glucuronide can be hydrolyzed through an enzymatic or non-enzymatic reaction to give the active aglycon [27] In this latter context glucuronidation has been used as for the preparation of SN-38 and taxol prodrugs. [27, 31] The strategy relies on the fact that β-glucuronidase is generally overexpressed in tumour tissues. In view of these interesting properties of glucuronides and of the possibility that in vivo generation of glucuronides can occur we decided to prepare the glucuronide of MGSTA-5. Thus, MGSTA-5, which had been prepared on 100 mg scale, was coupled with trichloroacetimidate 36 [32] using TMSOTf affording exclusively the protected βglucuronide 37. Simultaneous removal of benzoate protective groups and hydrolysis of the methyl ester using aqueous NaOH gave the macroketone β-glucuronide MGSTA-16. In order to obtain the α-anomer of this glucuronide we applied the chelation induced anomerization [33] , which has been of interest in our laboratory [33d] for the synthesis of the α-glucuronide. Thus, glucuronide 37 was treated with TiCl4 in CDCl3 at 4 o C giving the α-glucuronide 38 as the only product. Deprotection and ester hydrolysis gave MGSTA-17.
Synthesis of glutarimide containing analogues of migrastatin where alkene geometry is varied.
The preparation of MGSTA-18 and MGSTA-19, containing the glutarimide side-chain, where olefin geometry is modified in the macrocyclic core was included in the synthetic study. Thus, diene precursors were prepared from freshly prepared aldehyde 39 (Scheme 5) using Wittig reagent 40 to give the E-alkene 41 with high stereoselectivity (E:Z = 25:1); this reaction provided the isomer which would enable preparation of migrastatin analogues with an E-alkene at C-3 in the macrocycle. The subsequent steps were similar to those used by Danishefsky and co-workers [6, 17h] for their preparation of migrastatin. Thus, the reduction of the ester with DIBAL-H gave the corresponding allylic alcohol which was subsequently oxidized using the Dess-Martin reagent and the aldehyde generated was reacted with propionyl oxazolidinone 42 in the presence of MgCl2, triethylamine, and TMSCl to afford, after treatment with TFA, the desired anti-aldol product 43. Protection of the hydroxy group as a TES ether, and reductive removal of the auxiliary gave primary alcohol 44 in good yield (Scheme 5). The glutarimide aldehyde 47 needed for the introduction of the glutarimide chain was prepared from 45 via thioester 46 (Scheme 5). [34] With 44 in hand the preparation of 51 was next completed. Hence Dess-Martin oxidation of 44 gave the corresponding aldehyde which was reacted with the anion generated by reaction of dimethyl methylphosphonate with butyl lithium to give an alcohol intermediate. Oxidation of this alcohol afforded phosphonate 48. Then glutarimide aldehyde 47 was treated with 48 using the Masamune-Roush variant of the Horner-Wadsworth-Emmons reaction, giving the corresponding E-enone which was reduced with the Stryker reagent 50 and subsequent selective cleavage of TES protecting group gave alcohol 49 (Scheme 6). The synthesis of stereoisomers of migrastatin was possible with 49 in hand, as it had a trisubstituted alkene with the E-configuration (Scheme 6). Thus the modified Yamaguchi acylation from 2,6-heptadienoic acid gave 51. However, the subsequent RCM reaction, attempted using both the Grubbs-II and Hoveyda-Grubbs-II catalysts, did not give rise to a ring closed product. The coupling of 49 with 6heptenoyl chloride, which gave 52 was carried out. Substrate 52 does not contain the unsaturated ester and in this case the RCM reaction succeeded and gave the ring closed product as a mixture of E-and Z-stereoisomers (2:1), which were difficult to separate. Removal of the TBS group from the mixture was effectively achieved using HF-pyridine to give both 53a and 53b. The presence of both Z:E isomers in the mixture was deduced by alkene proton signals in the 1 H-NMR spectrum of the mixture of 53a and 53b with coupling constants J = 10.7 Hz (Z) and J = 15.2 Hz (E). Encouraged that the presence of the E-alkene in 52 did not totally preclude macrocycle formation by RCM, we revised the approach to MGSTA-18 and MGSTA-19. Danishefsky and his co-workers, in their total synthesis of isomigrastatin, [35] reported that RCM gave the 12-membered ring only when the alkene group adjacent to the carbonyl group was absent. They used an α-phenylselenide derivative and introduced the alkene adjacent to the carbonyl group after RCM. In order to obtain MGSTA-18 and MGSTA-19 the selenium containing acid 55 was therefore first prepared from commercially available 54 in two steps. Yamaguchi acylation of 49 with racemic 55 and subsequent removal of the TBS group provided a mixture of diastereoisomers 56. The RCM from 56 using the Grubbs-II reagent gave a 1:2 mixture of E-isomer 57a (not shown) and the Z-isomer 57b. The polarity of 57a and 57b was similar on TLC, but it was possible to separate small amounts of 57a and 57b through repeated chromatographic purification steps. However, despite repeated chromatography it was not possible to obtain these compounds with high purity at the scale at which the reaction was carried out. Thus the oxidative deselenation of the Z-isomer 57b was carried out with the material obtained and this gave the E-isomer MGSTA-19 in 42% yield, along with 23% of the Z-isomer MGSTA-18 (Scheme 7). The structural assignment for MGSTA-19 was supported by a typical α,β-unsaturated ester proton signal (δ 6.83) with J value typical of a Z-alkene (16.0 Hz) whereas MGSTA-18 had a signal at δ 6.23 and J value typical of E-alkene (11.1 Hz) .
Biological evaluation of migrastatin-core analogues
With a variety of congeners now prepared, biological studies were next carried out with the capacity of compounds to inhibit tumor cell migration investigated using both wound healing and transwell assays. Firstly, in order to eliminate the possibility that any decrease of migration was caused by an inhibition of cell proliferation or toxicity, rather than an interaction with the cell motility machinery, the effect of newly synthesized migrastatincore analogues on three breast (MCF7, MCF7-Dox, MDA-MB361) and one pancreatic cancer (HPAC) cell lines were evaluated using the MTT assay.
The newly synthesized analogues did not cause any toxicity or arrest of proliferation at the tested concentrations (1, 10 & 100 μM) (see supporting information provided). Therefore wound healing assays were next carried out to address the effect on cell migration following exposure to compounds. The migrastatin analogues when given at the concentration of 10 µM strongly inhibited migration of the low-invasive MCF7 [36] and doxorubicin resistant MCF7-Dox breast cancer cells, with average scratch closure of 14.6% and 14.9% respectively. Interestingly, treatment of MDA-MB361 breast cancer cells with migrastatin analogues resulted in the inhibition of cell migration with an average scratch closure of 42.0%. MDA-MB361 are known to have poor cell-cell adhesion. [36] As a result, some migrastatin analogues were tested on the MDA-MB-231 cell line, that display a more invasive phenotype, [36] and with this in vitro model, the average scratch closure was 63.3%. When the migrastatin analogues where tested on the pancreatic cancer cell line, HPAC, we noted an average of scratch closure of 33.5% (see supporting information).
Next a selected number of the compounds tumour cell migration inhibitory activity was evaluated using the Boyden chamber assay as this is considered a superior model with which to conduct cell migration studies. [1] Eight of the compounds were selected based on considering macrocycle ring size and other structural features: compounds MGSTA-13 and MGSTA-14 were selected because of their relationship to the isomigrastatin macrocyclic core; MGSTA-9 contains an extra carbon in the macrocyclic ring compared to migrastatin; MGSTA-6 possesses an α,β-unsaturated carbonyl group that is present in migrastatin; MGSTA-15 is the direct analogue of MGSTA-4 with a methyl group instead of a methoxy in the 9 position; MGSTA-16 and 17 are the glucuronides and MGSTA-5 (Danishesky's macroketone), was selected for use as the internal control. As shown in Figure  3 and 4, the selected compounds, inhibit cell migration in the less invasive MCF7 cells in the nanomolar range. The only exception was MGSTA-6 which inhibited cell migration with considerably lower potency (IC50 > 1µM) when compared with the macroketone MGSTA-5 (IC50 = 13 nM). The glucuronides were found to be less potent than the macroketone against this cell type with the βglucuronide more potent than its α-anomer. MGSTA-5,6 and 14 were tested using the more invasive MDA-MB361 cell line. Interestingly, MGSTA-6 (IC50 = 410 nM) was 2.4 fold more potent than MGSTA-5 (IC50 = 974 nM) in this particular cell line, contrasting with the result for the MCF7 cells. In addition, the isomigrastatin-core analogue MGSTA-14 strongly inhibited cell migration of MDA-MB361 cells (IC50 = 301 nM). MGSTA-5,6,9,15,16 and 17 all strongly inhibited cell migration in HPAC cells, however, the curve dose response was very wide and the IC50 could not be extrapolated. Thus, MGSTA-6 showed good cell migration inhibition in highly metastatic MDA-MB361 but not in less invasive MCF7 cells. This apparent paradox could be related with cytoskeleton proteins targeted by migrastatin analogues [9, 19] and with differents molecular changes occurring during the complex event of metastasis in invasive and non invasive cells. In a previous paper we showed that MGSTA-6 inhibited the formation and elongation of filopodia by interfering with fascin1-dependent cross-linking of actin filaments and subsequently leads to inhibition of stress fibres formation. [9] Importance of these cytoskeleton rearangements in cancer invasion indicates a correlation between high fascin expression and poor prognosis in human carcinomas. [37] Stress fibre formation is the last and crucial step of complex changes occuring in cytoskeleton of invasive cancer cell before its movement and it could tentatively explain the more pronounced biological activity of MGSTA-6 in MDA-MB361 cells.
In vitro pharmacological profile of MGSTA-6
The pharmacological profile of a biologically active small molecule can be classified into primary (interaction with the intendent target) and secondary (interactions with differents targets). Interaction with secondary targets can lead to adverse drug reaction (ADRs). From the drug discovery point of view, it is extremely important to identify the potential side effects as early as possible. Recently, [38] it has been suggested that drug candidates should be screened against a variety of targets (receptors, ion channels, enzymes and transporters). Compounds that interact with several of the above mentioned targets, are more prone to induce ADRs. Unsaturated macroketone MGSTA-6 strongly inhibits cell migration in MDA-MB361 and HPAC cells (see above) and was earlier shown to interfere with the fascin1-dependent cross-linking of actin filaments leading to inhibition of stress fibers formation in canine mammary cancer cells. [9] This agent was therefore selected from the panel of agents for screening against 55 targets (receptors, ion channels and transporters) known to be linked to ADRs. At the concentration of 10 µM, MGSTA-6 only showed weak inhibition of two targets: adenosine receptor A2A (27%) and prostanoid EP4 receptor (39%). It has been suggested [38] that compounds with a promiscuity index (percentage of targets giving more than 50% inhibition at 10 μM in a set of at least 50 targets) of more than 20% should be considered promiscuous and this has been linked to market withdrawal and clinical trial failure. Unsaturated macroketone MGSTA-6, with a promiscuity index between 0-5%, is a possible candidate as a tumour cell migration inhibitor with potentially low side effects. However, the pharmacological panel in this study does not include enzymes and further investigations would be necessary in order to confirm the selectivity of MGSTA-6 (Table S1 ).
Conclusions
The stereoselective synthesis of intermediates based on Brown allylation and alkoxyallylation has enabled the preparation of a series of migrastatin and isomigrastatin analogues. Chelation induced anomerisation is compatible with the various functionality found in the migrastatin macroketone skeleton and could be exploited to give macroketone glycosides for biological study.
Compounds showed inhibitory activity when tested against breast and pancreatic cancer cell lines (MCF-7, MCF7-Dox, MDA-MB631, MDA-MB261, HPAC) using the wound healing assay and Boyden chamber assay (nM range). One inhibitor (MGSTA-6) has low activity against a variety of receptors, ion channels and transporters, which indicates that it, and possibly other migrastatin analogues, may have potential to inhibit tumour metastasis without adverse drug reactions.
Experimental Section
General: NMR spectra were recorded on a 500 MHz spectrometer at (ddd, 1H, J 14.7, 8.8, 5.2 Hz, 5.41 (d, 1H, J5, 6 = 9.6 Hz, 5.17 (dd, 1H, J8, 9 = 7.3 Hz, 2H, 8) (2R,3R,4S)-2,4-dimethylhex-5-ene-1,3-diol (26) . To stirred t-BuOK (1.63 g; 14. 57 mmol) in THF (4 mL) at -45 o C n-butyllithium in heptane (9.1 mL, 14 .57 mmol, 1.6 M) was added. The mixture was cooled to -78 o C and βmethoxydiisopinocampheylborane (5.5 g, 17.4 mmol) in THF (17 mL) was added via cannula over The mixture was stirred at -78 o C for an additional 1h and boron trifluoride etherate (2.4 mL, 19.45 mmol) was added dropwise at -78 o C. Immediately, a solution of aldehyde 25 (3.94 g, 20.52 mmol) in THF (7 mL) was added, and the mixture was stirred at -78 o C for 18 h. Then aqueous NaOH (10.66 mL; 32 mmol, 3M) was added followed by H2O2 (4.5 mL, 30%), and the biphasic mixture was allowed to warm to room temperature slowly and refluxed for 1h. The solution was diluted with CH2Cl2 and washed with water. Organic layer was separated, and then dried over Na2SO4 and the solvent was removed under reduced pressure.
The residue was subjected to silica gel chromatography (PE: EtOAc, 1:6) affording a mixture of the title compound and pinenol during the work-up (9.87 g) which can be used directly in the next step. The mixture (9.87 g) was dissolved in dry methanol (200 mL) and K2CO3 (2.32 g) was added.
After stirring at room temperature for 24 h AcOH was added until the pH = 7. The solvent was removed under reduced pressure and the residue was ( 9S,10R,11R,Z)-10-(methoxymethoxy)-9,11-dimethyloxacyclododec-7-en-2-one (MGSTA-11) . 1 H NMR (CDCl3, 1H, 5.34 (td, 1H, J7, 8 = 10.6, J6, 7 = 5.0 Hz, H-7), 4.67 (d, 1H, J = 6.6 Hz, OCH2O), 4.62 (d, 1H, J = 6.6 Hz, OCH2O), 4.38 (dd, 1H, J12, 12' = 11.4, J12, 11 = 3.1 Hz, , 3.89 (dd, 1H, J11, 12' = 5.2 Hz, 4H, OCH3), 2.71 (dqd, 1H, J8, 9 = 9.9, J9, Me = 6.8, J9, 10 = 2.9 Hz, 2.44 (ddd, 1H, J = 12.7, 8.5, 3.9 Hz, CH2), 2.33 (ddd, 1H, J = 13.3, 8.9, 3.7 Hz, CH2), 2.26 -2.14 (m, 1H, CH2), 2.14 -2.02 (m, 1H, H-11), 1.91 -1.75 (m, 2H, CH2), 1.64 (dddt, 2H, J = 20.6, 8.7, 5.8, 3.2 Hz, CH2), 1.42 -1.29 (m, 1H, CH2), 1.11 (d, 3H, J = 7.3 Hz, CH3 at C-11), 0.98 (d, 3H, J = 6.8 Hz, H-CH3 at C-9); 13 (9S,10R,11R,E)-10-(methoxymethoxy)-9,11-dimethyloxacyclododec-7-en-2-one (MGSTA-12). 1 H NMR (CDCl3, 500MHz) δ 5.42 (ddd, 1H, J7, 8 = 14.9, 8.3, 6.3 Hz, H-7), 5.25 (dd, 1H, J8, 9 = 8.2 Hz, 2H, OCH2O), 4.47 (dd, 1H, J12, 12' = 10.6, J11, 12 = 2.9 Hz, 3.54 (appt, 1H, J12, 12' = J11, 12' = 10.7 Hz, (9S,10R,11R,E)-10-hydroxy-9,11-dimethyloxacyclododec-7-en-2-one   (MGSTA-14) . To stirred MGSTA-12 (23.4 mg; 0.087 mmol) in CH2Cl2 (6 mL), TMSBr (23 µL; 0.174 mmol) was added at -20 o C. The mixture was stirred for 2 h. Satd NaHCO3 was added and the solution was extracted with CH2Cl2 (3 x 10mL) and the combined organic layers were dried and the solvent was removed under reduced pressure. Purification by FC (EtOAc/Cy 1:10) gave MGSTA-14 (14.5 mg, 74 %) as a colourless oil.
[α]D 6.49 o (c 0.99, CHCl3); 1 H NMR (CDCl3, 500MHz) δ 5.44 (ddd, 1H, J7,8 = 14.6, J7,6 = 8.0, J7,6' = 6.4 Hz, H-7), 5.28 (dd, 1H, J8, 9 = 8.1 Hz, 4.41 (dd, 1H, J12, 12' = 10.7, 2.8 Hz, (7E,9S,10R,11R,12Z)-10-hydroxy-9,11,13trimethyloxacyclotetradeca-7,12-dien-2-one (MGSTA-15) . To a stirred solution of 34 (8.7 mg; 0.028 mmol) in CH2Cl2 (5 mL 2H, ArH), 5.94 (appt, 1H, J2', 3' =J3', 4' = 9.6 Hz, H-3'), 5.69 (dd, 1H, J3', 4' = J4', 5' = 9.7 Hz, 3H, 10), 5.23 (dd, 1H, J9, 10trans = 15.7, J8, 9 = 7.5 Hz, 5.21 (d, 1H, J1', 2' = 7.9 Hz, H-1'), 4.27 (d, 1H, H-5') , 3.69 (s, 3H, OMe), 2H, 8) 9.6, 4.8 Hz, 5.44 (dd, 1H, J8, 9 = 9.0 Hz, 5.37 (d, 1H, J5, 6 = 9.2 Hz, H-5), 4.44 (d, 1H, J1',2' = 7.9 Hz, H-1'), 3.85 (appt, 1H, H-8) , 3.60 (d, 1H, J4', 5' = 9.3 Hz, 3H, 3', 4'), 3.37 (dd, 1H, J2', 3' = 7.8 Hz, ArH), 6.27 (appt, 1H, J2',3' = J3',4' = 9.9 Hz, H-3'), 5.71 (ddd, 1H, J9,10 = 14.9, 8.4, 5.9 Hz, H-10), 5.58 (t, 1H, J4', 5' = 10.0 Hz, 5.45 (d, 1H, J1', 2' = 3.7 Hz, H-1'), 5.37 (dd, 1H, 5.31 (dd, 1H, J8, 9 = 8.1 Hz, 5.21 (d, 1H, 4.80 (d, 1H, J5, 6 = 9.6 Hz, 
MGSTA-18 and MGSTA-19.
To 57b (21 mg, not fully pure, <32.5 μmol,) at -78°C in 2.5 mL CH2Cl2, mCPBA (≤77%, 7.6 mg, 33.9 μmol) in CH2Cl2 (2.5 mL) was added. After 30 minutes at -78°C, TLC (PE/EtOAc 1:1.5) showed only baseline material.
iPr2NEt (6.8 μL, 39 μmol) was then added and the mixture was allowed to warm to room temperature over 10 minutes. After 2 hour at room temperature, TLC showed there still have baseline material, so more iPr2NEt (7 μL) was added. After 1 h the mixture was concentrated under reduced pressure and purified by chromatography on silica eluting with PE-EtOAc (1:1.5) to give MGSTA-19 (4.7 mg) and MGSTA-18 (8.5 mg) in 65% yield for 2 steps. 5-((2R,3E,5R,6S,7S,8Z,12Z) 5-((2R,3E,5R,6S,7S,8Z,12E) Windows, USA). The migration rate was expressed as percentage of scratch closure and was calculated as follows: % of scratch closure= ab/a, where (a) is a distance between edges of the wound, and (b) is the distance which remained cell-free during cell migration to close the wound [39] . The values are presented as means of three independent wound fields from three independent experiments (n= 9).
Analytical data for 4-((S)-

Trans-well migration assay:
The Boyden chamber cell migration assay was performed using the BD Falcon™ FluoroBlock™ 24-Multiwell Insert Plates (8 micron pore size) (BD Biosciences, USA). Firstly, cells ( 1×10 5 ) were suspended in FBS free medium and added to the apical chambers of an insert plates (500 μl). Then 750 μl of chemoattractant (10% FBS) was added to the basal chambers. Migrastatin analogues or DMSO (as a control) were added to the medium in both chambers. For dose-dependent studies MGSTA analogues were used in the range of concentration from 0.01 to 100 μM. Migration assays were carried out for 18-20 h at standard culture conditions. Then, medium was carefully removed from apical chamber and the insert system was transferred into a second 24-well plate containing 500 μl of 2.5 μg/ml Calcein AM in Hanks' Balanced Salt solution (HBSS). Plates were incubated for one hour at standard culture conditions.
Then, the fluorescence of migrated cells was measured at excitation wavelength 485 nm and emission wavelength 530 nm using florescent plate reader with bottom reading capabilities Infinite 200 PRO Tecan™ (TECAN, Switzerland). All samples were assayed in triplicate, and each experiment was conducted three times (n= 9). For each experiment two negative controls were used: (1) cells grown as given above without adding chemoattractant to the medium, and (2) medium added as described without cells. In order to determine fluorescence of cells that migrated through the membrane, plates were analysed using a fluorescence microscope (Olympus BX60, magnification x4).
In vitro pharmacology: Binding assays: Cell membrane homogenates are incubated with radioligand binding in the absence or presence of MGSTA-6 in a buffer. Non specific binding is determined in the presence of a specific agonist or antagonist at the target. Following incubation, the samples are filtered rapidly under vacuum through glass fiber filters presoaked in a buffer and rinsed several times with an ice-cold buffer using a 96-sample cell harvester. The filters are dried then counted for radioactivity in a scintillation counter using a scintillation cocktail. The results are expressed as a percent inhibition of the control radioligand specific binding. [40] 
